Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,459 | -9,159 | -4,817 | -17,565 | -12,431 |
| Depreciation Amortization | 377 | 238 | 100 | 99 | 69 |
| Other Working Capital | 944 | -319 | 44 | 1,309 | 354 |
| Other Operating Activity | 727 | 334 | 159 | 395 | 265 |
| Operating Cash Flow | $-12,411 | $-8,905 | $-4,514 | $-15,763 | $-11,743 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -36 | -31 | -13 | -101 | -73 |
| Investing Cash Flow | $-36 | $-31 | $-13 | $-101 | $-73 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 14,931 | 7,676 | 1,181 | 6 | 6 |
| Other Financing Activity | 0 | -136 | 0 | 0 | -226 |
| Financing Cash Flow | $14,931 | $7,540 | $1,181 | $6 | $-220 |
| Beginning Cash Position | 4,968 | 4,968 | 4,968 | 20,826 | 20,826 |
| End Cash Position | 7,453 | 3,573 | 1,623 | 4,968 | 8,791 |
| Net Cash Flow | $2,485 | $-1,396 | $-3,346 | $-15,857 | $-12,035 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,411 | -8,905 | -4,514 | -15,763 | -11,743 |
| Capital Expenditure | -36 | -31 | -13 | -101 | -73 |
| Free Cash Flow | -12,447 | -8,936 | -4,527 | -15,863 | -11,816 |